Efficacy of ibandronate: a long term confirmation

Area of Science:

• Pharmacology
• Bone Metabolism
• Clinical Osteoporosis Management

Background:

• Postmenopausal osteoporosis poses a significant fracture risk and socioeconomic burden.
• Bisphosphonates are a cornerstone of osteoporosis treatment.
• Ibandronate is an established treatment option, but long-term efficacy and adherence require ongoing evaluation.

Purpose of the Study:

• To evaluate the efficacy, safety, and tolerability of specific ibandronate regimens.
• To assess the sustained efficacy of oral and intravenous ibandronate over five years.
• To explore the impact of adherence on fracture protection and the economic burden of osteoporosis.

Main Methods:

• Analysis of data from randomized clinical trials, observational studies, and meta-analyses.
• Inclusion of treatment regimens, including those not licensed for standard practice.
• Evaluation of the MOBILE and DIVA LTE studies for sustained efficacy.
• Assessment of prescription database studies to evaluate adherence rates.

Main Results:

• Both 150 mg once-monthly oral and 3 mg quarterly intravenous ibandronate show significant efficacy, safety, and tolerability.
• These regimens, correlating with ACE ≥10.8 mg, demonstrate notable efficacy in preventing non-vertebral and clinical fractures.
• Sustained efficacy was confirmed over 5 years in the MOBILE (oral) and DIVA LTE (intravenous) studies.
• Improved adherence rates with monthly oral ibandronate are linked to enhanced fracture protection and reduced socioeconomic impact.

Conclusions:

• Marketed ibandronate regimens (150 mg monthly oral, 3 mg quarterly IV) are effective and well-tolerated for postmenopausal osteoporosis.
• Sustained efficacy over 5 years supports long-term use of these ibandronate formulations.
• Enhanced adherence to monthly oral ibandronate offers potential for improved fracture prevention and decreased healthcare burden.